Clinical - ABL SA : ABL SA

Read more

EMRs - Registries - Integration tool

Read more

Clinical solutions

Discover our solutions

Clinical applications

Discover our applications

New Publication on DeepChek®-HCV Drug Resistance Assays and Software (Virology Journal)

Jul 17, 2020

Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols Caputo et al. Virology Journal (2020) 17:103 https://doi.org/10.1186/s12985-020-01381-3 Abstract Background: Notwithstanding the efforts of direct-acting antivirals (DAAs) for…
Read more
ABL Appointed as the Exclusive Distributor of all NimaGen sequencing products for France, Belgium and Luxembourg

Jul 15, 2020

We are pleased to announce that Nimagen appointed ABL as its exclusive distribution partner for Sequencing Products in France, Belgium and Luxembourg. The partnership was formalized on March 17th 2020 and will help all labs involved in sequencing to get access to robust and cost-effective solutions…
Read more
Advanced Biological Laboratories (ABL) Releases the First & Unique Commercial CE-IVD Registered COVID-19 rRT-PCR Assay Validated also for Human Saliva Specimens

Jul 06, 2020

Single well rRT-PCR assay, including highly sensitive detection of 2 targets and housekeeping internal control, with full automation Luxembourg (Luxembourg), Metz (France), — July 06 — Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its UltraGene® Combo2Screen SARS-CoV…
Read more

SARS-CoV-2 PCR Assay Now Approved for Human Saliva Specimens

Jun 17, 2020

First rt-PCR detection kit CE marked for nasopharyngeal and saliva samples. Improve COVID-19 management with non-invasive, open and sensitive assay. Luxembourg (Luxembourg), Metz (France), — June 17 — Advanced Biological Laboratories (ABL) announced today the validation of its CE-IVD UltraGene® Com…
Read more
Highly Satisfactory Accuracy for the UltraGene Combo2Screen SARS-CoV-2 Assay on the QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study

May 29, 2020

We are pleased to announce that the UltraGene Combo2Screen SARS-CoV-2 Assay has obtained Highly Satisfactory results (with a 100% accuracy for qualitative detection of all QCMD blinded samples, including with lowest viral load) in the context of the QCMD 2020 Coronavirus Outbreak Preparedness EQA Pi…
Read more
Advanced Biological Laboratories Receives CE-IVD Registration for its UltraGene Combo2Screen SARS-CoV-2 Assay

May 21, 2020

Optimizing COVID-19 management through highly sensitive SARS-CoV-2 detection test. Luxembourg (Luxembourg), Metz (France) — May 21— Advanced Biological Laboratories (ABL) announced today the CE-IVD registration of its UltraGene® Combo2Screen SARS-CoV-2 assay, now available for in-vitro diagnostics u…
Read more

Advanced Biological Laboratories Receives CE-IVD Registration for its SANGER and for its NGS DeepChek®-HIV Genotyping Drug Resistance Assays

May 18, 2020

A unique and flexible solution adapted to all virology and microbiology laboratories LUXEMBOURG CITY (Luxembourg), METZ (France) — May 18th, 2020 — Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its DeepChek®-HIV assays, now available for in-vitro diagnostics. Intend…
Read more
UltraGene Combo2Screen SARS-CoV-2 Assay Now Supported by French ANSM

May 13, 2020

Luxembourg (Luxembourg), Metz (France), Boston (USA) — May 13 — Advanced Biological Laboratories (ABL) announced today that its RT-PCR test for COVID-19 detection UltraGene® Combo2Screen SARS-CoV-2 assay is now officially approved by the French ANSM (Agence nationale de sécurité du médicament) as a…
Read more
UltraGene Combo2Screen SARS-CoV-2 Assay Now CE-IVD Marked

May 07, 2020

Luxembourg (Luxembourg), Metz (France), Boston (USA) — May 7— Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its UltraGene® Combo2Screen SARS-CoV-2 assay is now available for in-vitro diagnostics use. This test is intended to be used for the qualitative detection of nuc…
Read more